Find the Right Market Report

Search thousands of industry reports, market insights, and research studies in one place.

Not sure where to start? Try one of these:
Explore healthcare market intelligence and industry insights
Towards Healthcare

U.S. AI in Biotechnology Companies and Strategic Joint Ventures

Date : 26 March 2026

Top Companies and Offerings in the U.S. AI in Biotechnology Market

U.S. AI In Biotechnology Market Companies are

Everything about the U.S. AI in Biotechnology Market, all in one place - Access the Dashboard

Company Overview

Company Description
NVIDIA Corporation This mainly offers BioNeMo, NVIDIA Clara, and DGX Cloud to speed up R&D, which lowers drug discovery time and spending. 
Recursion Pharmaceuticals It is a prominent clinical-stage TechBio company that uses AI, automation, and a vast proprietary dataset to push drug discovery
Schrödinger, Inc. Its offerings cover LiveDesign, Physics-Based Drug Discovery (FEP+), and AI-enabled Generative Modeling Initiatives.
Tempus AI This widely facilitates AI-powered genomic sequencing (DNA/RNA), pathology/radiology analysis, & therapeutic discovery.
Insilico Medicine It has explored Pharma.AI Platform, PandaOmics, Chemistry42, etc.
Atomwise A firm provides AI-enabled, structure-based drug discovery technology using convolutional neural networks.
BPGbio This leader offers AI-driven drug discovery, target identification, and biomarker discovery. 
Generate Biomedicines It highly leverages AI to develop protein-based therapeutics across immunology, oncology, & infectious diseases.
Verge Genomics  A company unveiled the CONVERGE platform, which combines AI, genomics, and in-house labs to foster drug discovery. 
Relay Therapeutics This primarily specializes in uniting AI, molecular motion simulations, & experimental biology through its proprietary Dynamo platform. 

Market Forecast 2026-2035

The U.S. AI in biotechnology market size was estimated at USD 2.15 billion in 2025 and is predicted to increase from USD 2.57 billion in 2026 to approximately USD 12.82 billion by 2035, expanding at a CAGR of 19.55% from 2026 to 2035.

U.S. AI In Biotechnology Market Size is USD 2.57 Billion in 2026.

Latest Investments & Alliances in the U.S. AI In Biotechnology Market

  • In October 2025, Algen Biotechnologies partnered with AstraZeneca to foster AI-driven drug discovery in immunology.
  • In September 2025, GSK plc invested $30 billion across the United States in advanced manufacturing facilities and AI and advanced digital technologies.
  • In August 2025, Debut secured $20M in investment to speed up the progression of its proprietary, AI-based ingredient discovery platform to expand skin longevity innovation & scale its formulation business in the US & Asia.

Recent Developments in the U.S. AI in Biotechnology Market

  • In March 2026, Dyno Therapeutics, Inc. unveiled Dyno Psi-Phi, a suite of AI-driven protein design tools to support therapeutic developers in designing sequence-based medicines.
  • In January 2026, insitro, the AI therapeutics company, acquired CombinAbleAI and rolled out insitro’s TherML (Therapeutic Machine Learning) platform. 

Ready to make better
healthcare business decisions?

Speak with a healthcare analyst about your research, consulting, or platform needs.

Talk to an Analyst Contact Sales